Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • zhaopeihua
    Member
    • Aug 2013
    • 18

    #1

    variant allele fraction

    hi:
    What are "variant allele fraction" when talking about somatic mutations?
  • lethalfang
    Member
    • Aug 2011
    • 95

    #2
    Originally posted by zhaopeihua View Post
    hi:
    What are "variant allele fraction" when talking about somatic mutations?
    The fraction of alleles in the sample that are mutations.
    For instance, if all cells contains the same heterogeneous mutation (e.g., 100% tumor cell purity if you're looking at tumor cells), the variant allele fraction would be 50% (half-half from each chromosome).

    Comment

    • zhaopeihua
      Member
      • Aug 2013
      • 18

      #3
      Originally posted by lethalfang View Post
      The fraction of alleles in the sample that are mutations.
      For instance, if all cells contains the same heterogeneous mutation (e.g., 100% tumor cell purity if you're looking at tumor cells), the variant allele fraction would be 50% (half-half from each chromosome).
      thanks for you reply,but I didn't fully understand this concept. Could you show me a detail example with computational process? thanks again

      Comment

      • lethalfang
        Member
        • Aug 2011
        • 95

        #4
        This is an example of an output in my somatic calling pipeline:

        Code:
        Variant Annotation	Gene	Exon	Codon	Chr	Position	Variant	N(A)	N(C)	N(G)	N(T)	T(A)	T(C)	T(G)	T(T)	QSS	Frequency
        nonsynonymous SNV	KRAS	exon2	G12A	chr12	25398284	G35C	0	83	0	0	1	37	12	0	57	0.24

        N(A), N(C), N(G), and N(T) stand for the number of calls for A, C, G, and T in the normal sample. T(A), T(C), T(G), and T(T) stand for the number of calls for A, C, G, and T in the tumor sample.

        So for the normal sample, there are 83 sequences where the base is called C, and 0 for everything else. So it's pretty clear that in the reference and the normal sample, the base is C.
        However, in the tumor sample, there are 37 calls for C (reference) and 12 calls for G (variant), so the variant frequency is 12/(12+37) = 0.245.
        Notice the variant is labeled G35C. That's because the coding strand is the minus strand, where the DNA reads use the plus strand.

        Anyway, how do you interpret 24.5%?
        Well, if I assume that
        1) the KRAS mutation is present in all tumor cells (just use this assumption as an example), and
        2) KRAS mutation is a heterozygous mutation, then
        The tumor sample must contain 1/2 non-tumor cells, because those cells give me half of the reference reads. Out of the remaining 1/2 are tumor cells, half of those chromosomes give me reference reads, and the other 1/2 chromosomes give me mutant reads.

        Comment

        • zhaopeihua
          Member
          • Aug 2013
          • 18

          #5
          Awesome, thanks!

          Comment

          • vd4mindia
            Member
            • May 2013
            • 40

            #6
            @lethalfang
            `Would you like to share the pipeline for finding somatic mutations. I have 2 samples, one low and one high grade tumor and its normal. I want to detect the point somatic mutations. I have already employed GATK, VarScan and Mutect, but I have some descrepancy when am looking at my Low grade tumor since it is 50% pure. So I would like to try something more and have a read statistics like you have shown to validate the hits. If its ok for you

            Comment

            • lethalfang
              Member
              • Aug 2011
              • 95

              #7
              Originally posted by vd4mindia View Post
              @lethalfang
              `Would you like to share the pipeline for finding somatic mutations. I have 2 samples, one low and one high grade tumor and its normal. I want to detect the point somatic mutations. I have already employed GATK, VarScan and Mutect, but I have some descrepancy when am looking at my Low grade tumor since it is 50% pure. So I would like to try something more and have a read statistics like you have shown to validate the hits. If its ok for you
              That's something I used to do a couple of years ago.
              I just had a script to get those information out of the Strelka output vcf file. I had all those Strelka out directories in a single location, and ran this script to "summarize" all mutation calls from all the samples:



              It also calls annovar, which has a hard-coded path within the script.

              Comment

              • virpericulosus
                Junior Member
                • Sep 2014
                • 3

                #8
                Just wondering: The T(A) isn't counted because the frequency is just for T(G) variants?

                Comment

                • vd4mindia
                  Member
                  • May 2013
                  • 40

                  #9
                  Originally posted by lethalfang View Post
                  This is an example of an output in my somatic calling pipeline:

                  Code:
                  Variant Annotation	Gene	Exon	Codon	Chr	Position	Variant	N(A)	N(C)	N(G)	N(T)	T(A)	T(C)	T(G)	T(T)	QSS	Frequency
                  nonsynonymous SNV	KRAS	exon2	G12A	chr12	25398284	G35C	0	83	0	0	1	37	12	0	57	0.24

                  N(A), N(C), N(G), and N(T) stand for the number of calls for A, C, G, and T in the normal sample. T(A), T(C), T(G), and T(T) stand for the number of calls for A, C, G, and T in the tumor sample.

                  So for the normal sample, there are 83 sequences where the base is called C, and 0 for everything else. So it's pretty clear that in the reference and the normal sample, the base is C.
                  However, in the tumor sample, there are 37 calls for C (reference) and 12 calls for G (variant), so the variant frequency is 12/(12+37) = 0.245.
                  Notice the variant is labeled G35C. That's because the coding strand is the minus strand, where the DNA reads use the plus strand.
                  I would just want to ask you in case you have have not other bases as 0 in normal in that case do you still calculate the variant allele frequency as the above? Variant allele frequency should be always considered for the reads having variant allele for the tumor sample divided by the total reads at that variant site? Right? Irrespective of the reads falling for other bases in normal samples as well right?

                  Comment

                  • lethalfang
                    Member
                    • Aug 2011
                    • 95

                    #10
                    Originally posted by vd4mindia View Post
                    I would just want to ask you in case you have have not other bases as 0 in normal in that case do you still calculate the variant allele frequency as the above? Variant allele frequency should be always considered for the reads having variant allele for the tumor sample divided by the total reads at that variant site? Right? Irrespective of the reads falling for other bases in normal samples as well right?
                    I considered "variant allele frequency" as the frequency of variant alleles in a given sample.
                    So the tumor's variant allele frequency does not care what's in the normal tissue, and vice versa.
                    That way, you can monitor the change in variant allele frequency between the tumor and the normal.

                    Comment

                    • vd4mindia
                      Member
                      • May 2013
                      • 40

                      #11
                      Thank you very much for the reply. That makes sense.

                      Comment

                      Latest Articles

                      Collapse

                      • SEQadmin2
                        Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
                        by SEQadmin2



                        CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

                        Despite this, “CRISPR helped turn genome editing from a specialized technique into
                        ...
                        07-31-2026, 11:01 AM
                      • SEQadmin2
                        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                        by SEQadmin2


                        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                        The systematic characterization of the human proteome has
                        ...
                        07-20-2026, 11:48 AM
                      • SEQadmin2
                        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                        by SEQadmin2



                        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                        ...
                        07-09-2026, 11:10 AM

                      ad_right_rmr

                      Collapse

                      News

                      Collapse

                      Topics Statistics Last Post
                      Started by SEQadmin2, Yesterday, 07:41 AM
                      0 responses
                      12 views
                      0 reactions
                      Last Post SEQadmin2  
                      Started by SEQadmin2, 08-03-2026, 10:13 AM
                      0 responses
                      30 views
                      0 reactions
                      Last Post SEQadmin2  
                      Started by SEQadmin2, 07-31-2026, 02:55 AM
                      0 responses
                      39 views
                      0 reactions
                      Last Post SEQadmin2  
                      Started by SEQadmin2, 07-24-2026, 12:17 PM
                      0 responses
                      26 views
                      0 reactions
                      Last Post SEQadmin2  
                      Working...